QL2106
/ Qilu Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
August 05, 2026
A Comparative Phase 1 Study to Evaluate the Pharmacokinetic and Safety of QL2106 vs Tremfye in Healthy Subjects
(clinicaltrials.gov)
- P1 | N=190 | Completed | Sponsor: Qilu Pharmaceutical Co., Ltd. | Active, not recruiting ➔ Completed | Trial completion date: Aug 2026 ➔ Apr 2026
Trial completion • Trial completion date
June 06, 2026
QL2106-301: A Phase 3 Clinical Study of QL2106 Injection
(clinicaltrials.gov)
- P3 | N=318 | Recruiting | Sponsor: Qilu Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open • Dermatology • Immunology • Psoriasis • Psoriatic Arthritis
April 07, 2026
A Phase 3 Clinical Study of QL2106 Injection
(clinicaltrials.gov)
- P3 | N=318 | Not yet recruiting | Sponsor: Qilu Pharmaceutical Co., Ltd.
New P3 trial • Dermatology • Immunology • Psoriasis • Psoriatic Arthritis
March 18, 2026
A Comparative Phase 1 Study to Evaluate the Pharmacokinetic and Safety of QL2106 vs Tremfye® in Healthy Subjects
(clinicaltrials.gov)
- P1 | N=190 | Active, not recruiting | Sponsor: Qilu Pharmaceutical Co., Ltd.
New P1 trial
1 to 4
Of
4
Go to page
1